Botulism

China Botulinum Toxin Type A Markets Report, 2015-2019 & 2020-2024 featuring Allergan & Lanzhou Institute of Biological Products

Retrieved on: 
Thursday, February 18, 2021
Botulism, Drugs, Toxins, Botulinum toxin, Neurotoxins, Medical specialties, Clostridium botulinum, Dirk Dressler

In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.

Key Points: 
  • In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.
  • According to this market research, Botulinum Toxin Type A has been growing rapidly since it entered China.
  • As the demand for Botulinum Toxin Type A is expanding, some medical institutions and beauty salons have begun to inject Botulinum Toxin Type A smuggled from South Korea, France, Germany, etc.
  • 2 Sales of Botulinum Toxin Type A in China, 2015-2019
    2.3 Sales of Botulinum Toxin Type A by Dosage Form in China, 2015-2019
    3 Analysis on Major Manufacturers of Botulinum Toxin Type A in China, 2015-2019
    3.3 Lanzhou Institute of Biological Products Co., Ltd.
    3.3.2 Sales of Lanzhou Institute of Biological Products Co., Ltd.'s Botulinum Toxin Type A in China
    4 Prices of Botulinum Toxin Type A in China, 2019-2020
    4.1 Average price of Botulinum Toxin Type A in China, 2019-2020
    4.3 Average price of Lanzhou Institute of Biological Products Co., Ltd.'s Botulinum Toxin Type A (Hengli)
    5 Prospects of China's Botulinum Toxin Type A Market, 2020-2024
    Lanzhou Institute of Biological Products Co., Ltd.

Maypharm Announces New Product METOX on Times Square in New York

Retrieved on: 
Tuesday, January 26, 2021
Drugs, Botulism, Branches of biology, Plastic surgery, Toxins, Botulinum toxin, Neurotoxins, Wrinkle, Metox radar detector

SEOUL,South Korea and NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Maypharm announces new botulinum toxin, METOX on January 26, 2021.

Key Points: 
  • SEOUL,South Korea and NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Maypharm announces new botulinum toxin, METOX on January 26, 2021.
  • METOX is an effective solution for smoothing any kind of wrinkles from moderate to severe, caused by daily active facial movements.
  • Maypharm successfully entered to a toxin market, announcing their own newly launched toxin on TheTimes SquareSpectacular digitalbillboard in New York.
  • Meanwhile, METOX 100U botulinum toxin A is using a technology of the 2nd generation, an upgraded technique which is called vacuum dehydration.

Maypharm Announces New Product METOX on Times Square in New York

Retrieved on: 
Tuesday, January 26, 2021
Drugs, Botulism, Branches of biology, Plastic surgery, Toxins, Botulinum toxin, Neurotoxins, Wrinkle, Metox radar detector

SEOUL,South Korea and NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Maypharm announces new botulinum toxin, METOX on January 26, 2021.

Key Points: 
  • SEOUL,South Korea and NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Maypharm announces new botulinum toxin, METOX on January 26, 2021.
  • METOX is an effective solution for smoothing any kind of wrinkles from moderate to severe, caused by daily active facial movements.
  • Maypharm successfully entered to a toxin market, announcing their own newly launched toxin on TheTimes SquareSpectacular digitalbillboard in New York.
  • Meanwhile, METOX 100U botulinum toxin A is using a technology of the 2nd generation, an upgraded technique which is called vacuum dehydration.

Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021

Retrieved on: 
Monday, January 25, 2021
Biotechnology, Other Health, Health, Cosmetics, Retail, Drugs, Plastic surgery, Toxins, Botulism, Glycosaminoglycans, Botulinum toxin, Branches of biology, Hyaluronic acid

We continue to build on our existing body of evidence, underscoring the potential of DaxibotulinumtoxinA for Injection to set a new standard in facial aesthetics treatments, said Roman Rubio, Senior Vice President of Clinical Development at Revance.

Key Points: 
  • We continue to build on our existing body of evidence, underscoring the potential of DaxibotulinumtoxinA for Injection to set a new standard in facial aesthetics treatments, said Roman Rubio, Senior Vice President of Clinical Development at Revance.
  • DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • "Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 19, 2021
Biotechnology, Pharmaceutical, Health, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Toxicology

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling an aggregate of 75,400 inducement restricted stock awards (RSAs) to 15 employees.

Key Points: 
  • Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling an aggregate of 75,400 inducement restricted stock awards (RSAs) to 15 employees.
  • Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    RHA resilient hyaluronic acid and RHA are trademarks of TEOXANE SA.

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications

Retrieved on: 
Friday, January 15, 2021
Biotechnology, Pharmaceutical, Health, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Ipsen, Neuroscience, Toxicology, spasticity, cervical dystonia, Dysport, Ipsen

These data showed the duration of response that Dysport can offer to patients decreases the chance of patients experiencing symptomatic recurrence before the next injection.

Key Points: 
  • These data showed the duration of response that Dysport can offer to patients decreases the chance of patients experiencing symptomatic recurrence before the next injection.
  • Follow Ipsen on Twitter via @IpsenGroup and keep up to date with TOXINS 2021 news and updates by using the hashtag #ina_toxins.
  • The Group develops and commercializes innovative medicines in three key therapeutic areas Oncology, Neuroscience, and Rare Diseases.
  • These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data.

Botox Gold Review: Latest Weight Loss Supplement That Works

Retrieved on: 
Tuesday, January 12, 2021
Drugs, Medical specialties, Clinical medicine, Plastic surgery, Botulinum toxin, Botulism, Neurotoxins, Obesity

Thus, drinking a supplement like Botox Gold can pose to be the ideal solution for everyone in this aspect.

Key Points: 
  • Thus, drinking a supplement like Botox Gold can pose to be the ideal solution for everyone in this aspect.
  • Each of these ingredients has its unique ability to enhance an individual's overall health and promote weight loss.
  • Most importantly, the manufacturer also perceives that the outcome of the usage of Botox Gold can vary from one person to another.
  • Thus, if someone is looking for an outright solution to their ever-growing obesity issue, then Botox Gold can be their go-to option.

Botox Gold Review: Latest Weight Loss Supplement That Works

Retrieved on: 
Tuesday, January 12, 2021
Drugs, Medical specialties, Clinical medicine, Plastic surgery, Botulinum toxin, Botulism, Neurotoxins, Obesity

Thus, drinking a supplement like Botox Gold can pose to be the ideal solution for everyone in this aspect.

Key Points: 
  • Thus, drinking a supplement like Botox Gold can pose to be the ideal solution for everyone in this aspect.
  • Each of these ingredients has its unique ability to enhance an individual's overall health and promote weight loss.
  • Most importantly, the manufacturer also perceives that the outcome of the usage of Botox Gold can vary from one person to another.
  • Thus, if someone is looking for an outright solution to their ever-growing obesity issue, then Botox Gold can be their go-to option.

Worldwide Industry for Botulinum Toxin to 2024 - Escalating Number of Plastic Surgeons is Driving Growth

Retrieved on: 
Thursday, January 7, 2021
Drugs, Botulism, Botulinum toxin, Neurotoxins, Toxins, Toxicology

The report provides a detailed regional analysis of the US, Europe, Japan, Asia (excluding Japan), Korea and China for the botulinum toxin market.

Key Points: 
  • The report provides a detailed regional analysis of the US, Europe, Japan, Asia (excluding Japan), Korea and China for the botulinum toxin market.
  • Growth of the overall global botulinum toxin market has also been forecasted for the period 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
  • The competition in the global botulinum toxin market is stiff and dominated by big players like Allergan.
  • The major growth drivers for the botulinum toxin market are: ageing population, escalating numbers of surgeons, upsurge in facial aesthetics procedures, rising alternative of non-surgical procedures, increasing healthcare spending in emerging markets.

CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine

Retrieved on: 
Thursday, January 7, 2021
Mammals, Fauna of Asia, Animals, Botulism, Preclinical development, Primate, Rhesus macaque, Macaque

NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytoDel, Inc. (CytoDel or the Company), a privately-held corporation, today announces the publication of preclinical data on the Companys lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine.

Key Points: 
  • NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytoDel, Inc. (CytoDel or the Company), a privately-held corporation, today announces the publication of preclinical data on the Companys lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine.
  • Following in vitro validation of therapeutic mechanisms, efficacy studies were conducted in mice, guinea pigs and rhesus macaque monkeys.
  • Post-symptomatic administration of B8C1ad produced antidotal rescue in mice, guinea pigs, and non-human primates following a lethal botulism challenge.
  • Ichtchenko and Band from NYU Grossman School of Medicine have financial interests in CytoDel and Dr.